Lanthio Pharma gets €3.6m Dutch loan for new lung fibrosis therapy
The loan will support the development of LP2, the first peptide-based drug , for treatment of Idiopathic Pulmonary Fibrosis. LP2 is an innovative lanthipeptide used to activate the
Boehringer Ingelheim has signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer.
AntiOp founder Dr. Daniel Wermeling said that this partnership leverages the company’s combined resources and strengths. "AntiOp has the technical expertise and R&D experience to deliver a specifically-designed
TD2 will study the effectiveness of Nuvilex’s pancreatic cancer treatment in relieving the unbearable pain and the accumulation of abdominal fluid known as ‘ascites’. Nuvilex’s pancreatic cancer treatment,